The iQ&A platform stresses:
Program Medium
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period March 2, 2017 through March 2, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 115 segments, totaling 3 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
3.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to improve the management of rheumatoid arthritis.
Release Date
March 2, 2017
Expiration Date
March 2, 2019
Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for rheumatoid arthritis.
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Rheumatoid Arthritis is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Michael H. Schiff, MD
Clinical Professor of Medicine
Rheumatology Division
University of Colorado School of Medicine
Denver, Colorado
Medical Director
Denver Arthritis Clinic Research Unit
Advisor or consultant: AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & John
son Pharmaceutical Research & Development, L.L.C.; Lilly USA, LLC; UCB Pharma, Inc.
Speaker or Speakers Bureau: AbbVie Inc.; Bristol-Myers Squibb Company
Daniel Furst, MD
Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA
Grant/Research Support: Abbott Laboratories, Actelion Pharmaceuticals Ltd, Amgen Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corp, and UCB Pharma, Inc.
Consultant: Abbott Laboratories, Actelion Pharmaceuticals Ltd, Amgen Inc., Biogen Idec, Bristol-Myers Squibb, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corp, Pfizer, Inc., and UCB Pharma, Inc.
Honoraria: Abbott Laboratories, Actelion Pharmaceuticals Ltd, Amgen Inc., Biogen Idec, Bristol-Myers Squibb, Genentech, Gilead Sciences, Inc., and Janssen Pharamaceuticals
Speakers’ Bureau: Abbott Laboratories, Actelion Pharmaceuticals Ltd, Amgen Inc., and UCB Pharma, Inc.
Yvonne Sherrer, MD
Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL
Speaker or Advisory Boards: Celgene, Amgen, Pfizer
Clinical Trials: UCB, Pfizer, Merck Serono, BMS, Resolve
Eric M. Ruderman, MD
Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois
Consulting: Abbvie, Amgen, Janssen, Lilly, Ledac, Pfizer, Vertex, Novartis, Pharmacyclics
Peter Nash, MD
Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia
Nothing to disclose
William J. Shergy, MD
Associate Clinical Professor of Medicine
University of Alabama at Birmingham
School of Medicine
Huntsville, Alabama
Assistant Consulting Professor of Medicine
Duke University Medical Center
Durham, North Carolina
Nothing to disclose
Ernest Choy, MD, FRCP
Head of Rheumatology and Translational Research
Institute of Infection and Immunity
Director of Arthritis Research UK CREATE Centre and
Welsh Arthritis Research Network (WARN) Cardiff University School of Medicine
Cardiff, United Kingdom
Nothing to disclose
Professor Tom W. J. Huizinga, MD, PhD
Head, Deptartment of Rheumatology
Leiden University Medical Center
Leiden, The Netherlands
Nothing to disclose
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic Cleveland, OH
Speaker or Consulting Honoraria: Roche, Genentech, Janssen, BMS, Abbvie
Richard M. Pope, MD
Mabel Green Myers Professor of Medicine
Chief, Division of Rheumatology
Northwestern University Medical School
Chicago, IL
Nothing to disclose
Michael Ehrenstein, MD
Professor of Rheumatology
University College Hospital
University College of London School of Medicine
London, UK
Nothing to disclose
Roy M. Fleischmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
Co-Director, Division of Rheumatology
Texas Health Presbyterian Medical Center and Co-Medical Director
Metroplex Clinical Research Center
Advisor or Consultant: AbbVie Inc.; Sanofi; UCB Pharma, Inc.
Grants/Research Support: AbbVie Inc.; Sanofi; UCB Pharma, Inc.
Jonathan Kay, MD
Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA
Membership on advisory committee or review panels: Alexion, Samsung Bioepis
Consulting: Abbvie; Ardea; Lilly; Pfizer, Inc., Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Co.; Crescendo Bioscience, Inc.; Epirus Biopharmaceuticals, Inc.; Genenetch; Hospira Janssen; Myriad Genetics, Inc.; PanGenetics, B.V; UCB, Roche Pharmaceuticals
Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will be able to: Compare and contrast the various technologies used to detect actionable mutational targets in cancer
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
Disclaimer
Copyright © 2017 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.